PIH28 AN EXAMINATION OF LOW AVERAGE DOSE AS A QUALITY MEASURE OF THE NEED FOR ANTICOAGULATION MANAGEMENT AMONG THE ELDERLY  by Banahan III, BF et al.
drug use based on therapeutic category, genitourinary products
were found to have the highest potential for inappropriate
prescribing.
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OBJECTIVE: Recent studies have demonstrated increased short-
term mortality among older adults with dementia who are pre-
scribed antipsychotic drug therapy. Despite these ﬁndings, use of
antipsychotics remains common in long-term care (LTC) homes.
This study explores the real-world implications of variations in
antipsychotic dispensing across LTC homes by assessing whether
homes with higher rates of dispensing had higher rates of mor-
tality among their residents. METHODS: Retrospective cohort
study of 47,308 older adults with no history of psychoses who
were newly admitted to 503 Ontario LTC homes between April
1, 2000, and March 31, 2004. Facilities were classiﬁed into
quintiles according to their mean antipsychotic dispensing rates.
All-cause mortality was examined across quintiles at 30 and 120
days after admission. RESULTS: The rate of antipsychotic dis-
pensing ranged from 0 to 44.8% across LTC homes. The abso-
lute baseline difference in 30-day (120-day) mortality between
facilities dispensing highest versus lowest rates of antipsychotics
was 1.4% (4.1%). Mortality was greater in the highest rate
homes (adjusted hazard ratio 1.29, conﬁdence interval 1.11 to
1.51 at 30 days; adjusted hazard ratio 1.28, conﬁdence interval
1.17 to 1.39 at 120 days) compared to the lowest rate homes.
CONCLUSION: Residents newly admitted to LTC homes with
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OBJECTIVE: The primary objective of this analysis was to
determine whether generic switching of warfarin was related to
increased hospitalization and emergency room use among elderly
chronic warfarin users. METHODS: The “switchability” of
narrow therapeutic index (NTI) drugs has been debated in the
literature. The issue is not whether generic products can safely be
substituted for brand products, but whether problems can result
from switches among manufacturers during repeated reﬁlls.
Medicare Part D and A records for 2006 were pulled for all
non-ESRD, chronic warfarin users in California, Florida, and
Mississippi age 65+. Chronic warfarin users were deﬁned as
patients with 3+ warfarin prescriptions covering 180+ days of
therapy. Recipients’ records were evaluated for hospital admis-
sions or ER visits during the treatment period. The hospital
services also were evaluated to determine if they resulted from
bleeding episodes or potential prophylactic use of warfarin based
on diagnosis codes. RESULTS: Data were available for 160,929
chronic warfarin users. After controlling for age, race, and
gender, the odds ratio for patients with generic switches com-
pared to those without was 1.61 for general hospital admissions
and 1.47 for general ER visits. Similar ratios were found for
hospital admissions related to bleeding episodes (1.51)/potential
prophylactic use (1.53) and ER visits related to bleeding episodes
(1.34)/potential prophylactic use (1.44). The average monthly
cost for hospital and ER services was 38% higher for the patients
with generic switches ($2121 vs. $1553). CONCLUSION: The
results suggest that generic switching of NTI drugs, such as
warfarin, can signiﬁcantly increase the likelihood of hospitaliza-
tion and ER visits and result in increased costs of care. To provide
better therapy management for patients on NTI drugs, pharma-
cists should avoid generic switching between manufacturers
and/or notify the appropriate providers when generic switches do
occur.
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OBJECTIVE: The objective was to evaluate the relationship
between low dose warfarin therapy and hospital utilization.
This information will help to evaluate this as a quality of care
indicator in elderly patients. METHODS: An issue in chronic
warfarin therapy is the availability of time and resources nec-
essary to adequately manage patients on anticoagulation
therapy. Providers may err on the side of under-dosing due to
fears of bleeding episodes. Medicare Part D and A records for
2006 were pulled for all non-ESRD, chronic warfarin users in
California, Florida, and Mississippi age 65+. Chronic warfarin
users were deﬁned as patients with 3+ warfarin prescriptions
covering 180+ days of therapy. Average dose was computed by
dividing the total mgs of warfarin dispensed from the ﬁrst pre-
scription to the next to last prescription and dividing by the
number of days between the ﬁrst and last prescription ﬁlls. Low
average dose was deﬁned as <=.5 mgs/day. Each recipient’s
records were evaluated for hospital admissions or ER visits
during the treatment period. RESULTS: Data were available for
160,929 chronic warfarin users. After controlling for age, race,
and gender, the odds ratios for patients on low average doses
compared to higher average doses were 1.42 for general hos-
pital admissions and 1.21 for general ER visits. The average
monthly cost for hospital and ER services was 85% higher for
the patients with low average doses ($2524 vs. $1364). CON-
CLUSION: The results indicate patients on average warfarin
doses of 2.5 mgs/day or less have greater odds of hospital
admissions or ER visits; and cost CMS more for these services.
This suggests that low average dose warfarin therapy is a
potential indicator that these patients are in need of better care;
and that CMS should consider payment for anticoagulation
management services that will maintain therapeutic INR levels
while minimizing bleeding risks.
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OBJECTIVE: Little is known about the quality of drug admin-
istration and safety in German nursing homes. In 2002 a group
of health authority pharmacists in the federal state of North
Rhine-Westphalia inspected the quality of drug supply in 120
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